Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin (BI 1356) plus pioglitazone versus pioglitazone plus placebo in type 2 diabetes
2007-002456-41Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Linagliptin + pioglitazone with Placebo + pioglitazone (2 arms). Primary endpoint: Change from baseline in HbA1c at 24 weeks. Started Jan 2008; status: completed.
02
Drugs
linagliptinpioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2007-002456-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002456-41.